Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tovinontrine - Cardurion Pharmaceuticals

Drug Profile

Tovinontrine - Cardurion Pharmaceuticals

Alternative Names: 68722; AF68722; CK1598; CRD-750; IMR-687

Latest Information Update: 01 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lundbeck A/S
  • Developer Enliven Therapeutics
  • Class Antianaemics; Heart failure therapies; Imidazoles; Pyrans; Pyrazines; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Phosphodiesterase 9A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Beta-thalassaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic heart failure
  • Discontinued Beta-thalassaemia; Sickle cell anaemia

Most Recent Events

  • 31 Mar 2024 Phase-II clinical trials in Chronic heart failure in USA (PO) (NCT06215586)
  • 21 Mar 2024 Cardurion Pharmaceuticals initiates a phase II Cycle-1-REF trial for Heart failure (PO, Tablets) as of March 2024 (NCT06215911)
  • 30 Jan 2024 Cardurion Pharmaceuticals plans a phase II Cycle-2-PEF trial for Heart failure (PO, Tablet) (NCT06215586)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top